Apnimed Statistics
Total Valuation
Apnimed has a market cap or net worth of $1.52 billion. The enterprise value is $1.51 billion.
| Market Cap | 1.52B |
| Enterprise Value | 1.51B |
Important Dates
The next estimated earnings date is Monday, August 31, 2026, after market close.
| Earnings Date | Aug 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Apnimed has 55.42 million shares outstanding. The number of shares has increased by 127.88% in one year.
| Current Share Class | 55.42M |
| Shares Outstanding | 55.42M |
| Shares Change (YoY) | +127.88% |
| Shares Change (QoQ) | +701.06% |
| Owned by Insiders (%) | 0.96% |
| Owned by Institutions (%) | 17.58% |
| Float | 36.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.63 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 12.56 |
| EV / EBITDA | 36.49 |
| EV / EBIT | 36.51 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.91
| Current Ratio | 1.91 |
| Quick Ratio | 1.17 |
| Debt / Equity | n/a |
| Debt / EBITDA | 0.94 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 108.70% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $1.85M |
| Profits Per Employee | -$489,631 |
| Employee Count | 65 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 47.54 |
| Average Volume (20 Days) | 556,257 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Apnimed had revenue of $120.15 million and -$31.83 million in losses. Loss per share was -$6.28.
| Revenue | 120.15M |
| Gross Profit | 112.61M |
| Operating Income | 41.34M |
| Pretax Income | 39.00M |
| Net Income | -31.83M |
| EBITDA | 41.36M |
| EBIT | 41.34M |
| Loss Per Share | -$6.28 |
Balance Sheet
The company has $46.89 million in cash and $39.35 million in debt, with a net cash position of $7.54 million or $0.14 per share.
| Cash & Cash Equivalents | 46.89M |
| Total Debt | 39.35M |
| Net Cash | 7.54M |
| Net Cash Per Share | $0.14 |
| Equity (Book Value) | -58.18M |
| Book Value Per Share | -53.95 |
| Working Capital | 37.17M |
Cash Flow
| Operating Cash Flow | -69.19M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 26,000 |
| Net Borrowing | 35.00M |
| Free Cash Flow | -69.19M |
| FCF Per Share | -$1.25 |
Margins
Gross margin is 93.73%, with operating and profit margins of 34.41% and -26.49%.
| Gross Margin | 93.73% |
| Operating Margin | 34.41% |
| Pretax Margin | 32.46% |
| Profit Margin | -26.49% |
| EBITDA Margin | 34.43% |
| EBIT Margin | 34.41% |
| FCF Margin | n/a |
Dividends & Yields
Apnimed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -127.88% |
| Shareholder Yield | -127.88% |
| Earnings Yield | -2.10% |
| FCF Yield | -4.56% |
Analyst Forecast
The average price target for Apnimed is $50.50, which is 84.51% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $50.50 |
| Price Target Difference | 84.51% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 63.78% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Apnimed has an Altman Z-Score of -2.03. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.03 |
| Piotroski F-Score | n/a |